Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized, Open-label, phase3 Trial Comparing Amrubicin Combined With Cisplatin Versus Etoposide-Cisplatin as First-line Treatment in Patients With Extensive Disease SCLC.

Next Previous
Trial Profile

Randomized, Open-label, phase3 Trial Comparing Amrubicin Combined With Cisplatin Versus Etoposide-Cisplatin as First-line Treatment in Patients With Extensive Disease SCLC.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 25 Jul 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Amrubicin (Primary) ; Cisplatin; Etoposide
  • Indications Small cell lung cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors Sumitomo Pharma

Most Recent Events

  • 04 Jun 2013 Preliminary results presented at the 49th Annual Meeting of the American Society of Clinical Oncology.
  • 05 Sep 2012 Data from this trial was used in support of an imported drug registration application cancer in China for amrubicin to the State Food and Drug Administration for the treatment of small cell lung cancer on 21 August 2012.
  • 05 Aug 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top